- Investigator, Genetics Branch
Dr. Caplen was awarded her Ph.D. from the University of London (Kings College Hospital Medical School) for studies on the genetics of type I diabetes and its complications. Dr. Caplen's Postdoctoral training began at St Mary's Hospital Medical School, Imperial College, where she focused on the development of gene therapy approaches for cystic fibrosis (CF) during which she was involved in some of the first pre-clinical and clinical studies of cationic lipid mediated gene therapy for CF. In 1996, Dr. Caplen came to the National Human Genome Research Institute (NHGRI) at NIH as a Visiting Fellow, where she initially conducted studies investigating hybrid viral vector systems for the delivery of genes. It was while at NHGRI that Dr. Caplen developed a research interest in the newly identified gene silencing mechanism, RNA interference (RNAi) leading to her studies that help establish the presence of RNAi in mammalian cells. Dr. Caplen joined CCR, NCI in 2004 as a Senior Scientist, where she pioneered approaches for exploiting RNAi to investigate cancer biology and treatment and helped establish a trans-NIH facility for genome-wide RNAi screening. Dr. Caplen was appointed a Tenure-Track Investigator in CCR’s Genetics Branch in January 2016. Her current research focuses on using functional genetic methods to interrogate specific aspects of the genetic, transcriptional, and signaling alterations observed in cancers driven by fusion oncogenes.
- (2011). A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets. INTERNATIONAL JOURNAL OF CANCER. 128(5), 1069-1079.
- (2011). Genomic instability and mouse microRNAs. TOXICOLOGY MECHANISMS AND METHODS. 21(4), 325-333.
- (2011). Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. BREAST CANCER RESEARCH AND TREATMENT. 130(2), 663-679.
- (2011). RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors. CURRENT CANCER DRUG TARGETS. 11(8), 976-986.
- (2010). Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. BREAST CANCER RESEARCH AND TREATMENT. 122(2), 347-357.